Ocular anterior segment inflammation is a medical problem that is seen in cases of cataract surgery and non-infectious anterior uveitis. Inadequately treated anterior segment inflammation can lead to sight-threatening conditions such as corneal oedema, glaucoma and cystoid macular oedema. The mainstay of treatment for anterior segment inflammation is topical steroid eye-drops. However, several drawbacks limit the critical value of this treatment, including low bioavailability, poor patient compliance, relatively difficult administration manner and risk of blurring of vision and ocular irritation. A drug delivery system (DDS) that can provide increased bioavailability and sustained delivery while being specifically targeted towards inflamed ocular tissue can potentially replace daily eye-drops as the gold standard for management of anterior segment inflammation. The various DDS for anti-inflammatory drugs for the treatment of anterior segment inflammation are listed and summarised in this review, with a focus on commercially available products and those in clinical trials. Dextenza, INVELTYS, Dexycu and Bromsite are examples of DDS that have enjoyed success in clinical trials leading to FDA approval. Nanoparticles and ocular iontophoresis form the next wave of DDS that have the potential to replace topical steroids eye-drops as the treatment of choice for anterior segment inflammation. With the current relentless pace of ophthalmic drug delivery research, the pursuit of a new standard of treatment that eliminates the problems of low bioavailability and patient compliance may soon be realised.

中文翻译：

---

药物输送系统治疗眼前节炎症的临床应用综述

眼前节炎症是一个医学问题，在白内障手术和非感染性前葡萄膜炎病例中可见。前段炎症治疗不当会导致危及视力的疾病，例如角膜水肿、青光眼和黄斑囊样水肿。眼前节炎症的主要治疗方法是外用类固醇滴眼液。然而，一些缺点限制了这种治疗的关键价值，包括生物利用度低、患者依从性差、给药方式相对困难以及视力模糊和眼部刺激的风险。一种药物递送系统 (DDS) 可以提供更高的生物利用度和持续递送，同时专门针对发炎的眼部组织，它有可能取代日常滴眼液，成为治疗眼前节炎症的金标准。本综述列出并总结了用于治疗眼前节炎症的各种抗炎药 DDS，重点关注市售产品和临床试验产品。Dextenza、INVELTYS、Dexycu 和 Bromsite 是在临床试验中取得成功并获得 FDA 批准的 DDS 的例子。纳米颗粒和眼部离子电渗疗法形成了下一波 DDS，它们有可能取代局部类固醇滴眼剂作为眼前节炎症的首选治疗方法。